Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
MOREPENLAB
Mr. Sushil Suri B.Sc., F.C.A. · Gurugram, India
₹57.85
▲+4.61%MOREPENLAB is trading near its 52-week high with strong volume, likely driven by positive momentum in the specialty generic drugs segment.
Exchange
NSI
Currency
INR
Day range
₹55.00 – ₹58.00
52-week range
₹33.05 – ₹64.58
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis65% confidence
The stock appears fairly valued at current levels, trading near its 52-week high with a P/E of 33.44, which may already factor in expected growth in the specialty generic segment.
10.4% below the 1-year high · trend up
Hedge-fund memo
Today
Up 4.61% with high volume, approaching resistance at 58 INR
This week
Gaining momentum, testing upper end of recent trading range
This month
Consistent upward trend, up approximately 12% over the past month
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
1 headlines · 1 outlets · 7d
TradingView·4d ago·revenue breakdown neutral
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 3 recent quarters (EPS actual vs. consensus).
0.16 vs 0.17
-5.88% surprise
0.09 vs 0.24
-62.50% surprise
0.21 vs 0.17
23.53% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| MOREPENLAB | 31.70B | 33.44 | 7.86% | 3.86% | 4.00% |
| MARKSANS | 117.57B | 28.17 | 15.16% | 19.99% | 20.80% |
| HFCL | 296.20B | 50.41 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory hurdles affecting product approvals
Mitigation: Diversify product pipeline and strengthen regulatory compliance team
Pricing pressure in generic markets
Mitigation: Focus on higher-margin specialty products and emerging markets
Business intelligence
Competitive moat
Moderate competitive advantage through established distribution network and cost-effective manufacturing capabilities in generic formulations
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
USFDA approvals for key products
Expansion in specialty generic segment
Thesis builder
Bull case
Growth in specialty generic drugs segment and operational efficiency improvements drive revenue and margin expansion
Base case
Stable performance in domestic markets with moderate growth in international operations
Bear case
Pricing pressure in generic markets and regulatory hurdles limit growth potential
Time horizon
12-18 months
Est. CAGR
8-12%
Entry (qual.)
Wait for pullback to 50-52 INR range for better risk-reward
Exit (qual.)
Consider taking profits above 62 INR near 52-week high
Overall conviction 65%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how MOREPENLAB fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain MOREPENLAB for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Hold with caution given the high valuation and strong recent price appreciation
Annual income statement, oldest → newest. Live via Yahoo.
| 18.95% |
| 119.90% |
| TRIDENT | 126.68B | 31.87 | — | 13.34% | 4.70% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹55.00
Resistance (day/52w high)
₹58.00
Volume
60,61,479
Trend
up
RSI (14)
42
MACD
bearish
MA cross
golden
50-day MA
₹52.33
200-day MA
₹43.92
vs 200-DMA
31.7%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.